Glenmark Generics Europe announces the launch of its first Four Products for the UK market

Date: 28 October 2009

Glenmark Generics Europe announces the launch of its first Four Products for the UK market 

·        The launch holds significance as these are Glenmark’s first products for the UK market in its own livery

·        Of the four products launched, Topiramate was a Day One launch and for Mometasone, Glenmark is the first generic in the UK market.  

October 27, 2009: Glenmark Generics (Europe) Ltd(GGEL), Glenmark Generics Limited’s (GGL) UK subsidiary has launched its first four products in the United Kingdom.  

This is the first time GGEL has launched products in its own livery in the UK. All these products will be sold directly by the UK subsidiary and through it’s own front end. This will increasingly supplement the revenue stream for GGEL which has traditionally relied on Dossier Licensing and Third Party Commercial Supplies to leading generic companies operating in Europe.  

Of the four products launched, Topiramate Tablets (25mg, 50mg,100mg, 200mg)  was launched on September 24, 2009 which was Day 1 of patent expiry in the UK market (IMS* market size : Euro 21 million). The other products launched include Nebivolol 5mg tablets (IMS* market size : Euro 6.8 million), Perindopril tablets (2mg, 4mg, 8mg) (IMS* market size :  Euro 88 million) and Mometasone ointment 0.1% (30gms,100gms) (IMS* market size Euro 3.5 million). Glenmark is the only company marketing the generic product in the UK market for Mometasone ointment while for Perindopril, the launch is an addition to third party business existing since last year when the product was launched 

Terrance Coughlin, Chief Executive Officer, Glenmark Generics Limited commented “We are delighted to now have our direct presence in the UK market. We have invested in developing infrastructure and getting the team in place for the long term implementation of our strategy for the Europe generic market. We will continue to expand our product range in the coming months by developing products where we are vertically integrated and also develop products & packs that will help with patient compliance to therapeutic regimes.” 

Glenmark Generics (Europe) Ltd headquartered in the UK operates through its own sales infrastructure in the UK and through licensing & distribution arrangements in other European markets. The UK office based in Hatfield possesses the infrastructure to support licensing, regulatory submissions, project management and sales and distribution in the UK and across Europe. For commercial enquires please contact our sales and marketing team based at our European Headquarters in Hatfield, Hertfordshire, UK on +44 1707 630909 

(*IMS market size is based on December 2008 data for the product in the UK market) 

About Glenmark Generics Ltd.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 65 countries, including the US, various countries in the EU, South America and India. 

About Glenmark Pharmaceuticals Ltd.

 Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.], Metabolic Disorders [diabetes, obesity, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.  

 Disclaimer“Glenmark Generics Limited (“Company”) is proposing, subject to market conditions and other considerations, a public issue of its equity shares and has filed a Draft Red Herring Prospectus with SEBI. The Draft Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in and the respective websites of the BRLMs at www.enam.com and www.kmcc.co.in.   Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled “Risk Factors” of the aforementioned Draft Red Herring Prospectus.” 

###

For further information, please contact: 

Jason D’Souza  

Glenmark, Mumbai, India Tel: [+91 22] 40189919 / 40189993 Email :  connect@glenmark-generics.com

Download PDF